RemeGen has had a bumpy ride, with the share price down over shorter periods but still showing a strong gain over three years. For anyone tracking the stock, the key issue now is whether the current market value lines up with the cash flows the business can realistically generate.
-
The stock has risen 78.1% over the past 3 years. That places a lot of weight on whether its future cash flows can support that kind of long stretch in performance.
-
The business model depends heavily on turning its drug pipeline and existing portfolio into recurring revenue. This can shape both the timing and durability of cash flows that feed into any intrinsic value estimate.
-
If you'd rather focus on earnings, this one's for you. See what RemeGen's 5.4x P/E says about the price .
For investors, the debate is whether RemeGen's recent share price, including the declines over the past year, is justified by the cash flows implied by a Discounted Cash Flow (DCF) view.
If you want to stress test whether RemeGen's cash flow story justifies its share price, compare it with a wider group of 195 high quality undervalued stocks
Does RemeGen Look Undervalued on Cash Flow?
The Discounted Cash Flow (DCF) approach here focuses on the cash RemeGen can return to shareholders over time. Latest twelve month free cash flow sits at about CN¥3.8b, and the model assumes this cash generation continues with growing but moderating free cash flow over the next decade rather than a sharp surge or collapse.
On those projections, the DCF outcome sits substantially above the current HK$65.90 share price. The gap comes from the model treating RemeGen as a business that is already generating sizeable cash in CN¥ and then gradually increasing those cash flows, rather than needing a dramatic turnaround story. For anyone weighing the recent share price swings against the underlying cash profile, the model suggests the market is not fully reflecting those projected CN¥ flows at today's level. Find out what RemeGen could be worth using our Discounted Cash Flow (DCF) estimate .
The RemeGen Narrative: What Would Justify Today's Price?
Narratives sit between that DCF gap and RemeGen's current share price and explain what would need to happen to growth, margins and earnings for the stock to be worth materially more or less than it is today. Each scenario links a specific fair value to a clear view of RemeGen's potential catalysts and main risks so you can monitor over time which version of the story aligns with what actually occurs on the Community page.
A clear, written Narrative on RemeGen makes the cash flow assumptions explicit so you can test, over time, whether its growth, margins and execution line up with the numbers in the model. With that kind of roadmap, each new data point becomes a way to confirm or challenge the story you are using to justify RemeGen's current share price.
Share your own Narrative for RemeGen and set out the assumptions behind your valuation.
Before making a move on RemeGen, there is one more piece to check
Cash flow models only tell part of the story, because the people steering RemeGen and how they are rewarded can heavily influence how those numbers play out over time. See who runs RemeGen and how they are paid .
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include 9995.HK .
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
